Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.80 |
| ▸ | SMO | Q99835 | 15/20 | 0.80 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351834 | 0.89 | MAPK14 (1.00) | MAPK14SMO | |
| SCHEMBL3687987 | 0.83 | MAPK14 (0.68) | MAPK14SMORIPK2 | |
| SCHEMBL3685192 | 0.83 | MAPK14 (0.76) | MAPK14SMORIPK2 | |
| SCHEMBL3685018 | 0.81 | SMO (0.80) | MAPK14SMO | |
| SCHEMBL3687608 | 0.79 | MAPK14 (0.66) | MAPK14SMORIPK2 | |
| SCHEMBL25211422 | 0.79 | MAPK14 (0.79) | MAPK14SMONPC1SMN1; SMN2 | |
| SCHEMBL30445799 | 0.79 | MAPK14 (0.79) | MAPK14SMONPC1SMN1; SMN2 | |
| SCHEMBL31326473 | 0.79 | MAPT (0.59) | MAPK14SMONPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14809997 | 0.78 | NPC1 (0.60) | MAPK14SMONPC1CASP3RAB9A | |
| SCHEMBL3648249 | 0.78 | CTDSP1 (0.61) | MAPK14SMONPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| EP-2188255-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | AstraZeneca AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009027746-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | SHH, GLI1, HRH4 | MAPK14 1705/4885SMO 6/4885RIPK2 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.